Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
about
St John's Wort (Hypericum perforatum L.) photomedicine: hypericin-photodynamic therapy induces metastatic melanoma cell deathInterferon alpha for the adjuvant treatment of cutaneous melanomaInterferon alpha for the adjuvant treatment of cutaneous melanomaTreatment of metastatic melanoma: an overviewClinical utility of nivolumab in the treatment of advanced melanomaMelanoma: new insights and new therapiesEvidence of gamma-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cellsThe combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53Ipilimumab: from preclinical development to future clinical perspectives in melanoma.Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in SwitzerlandSystems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells.Targeting Akt3 signaling in malignant melanoma using isoselenocyanates.Results of systemic treatment of cutaneous melanoma in inoperable stage III and IVTargeted Therapy Database (TTD): a model to match patient's molecular profile with current knowledge on cancer biologyCritical role of STAT3 in melanoma metastasis through anoikis resistanceEfficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis.Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma.Metastatic melanoma - a review of current and future drugsTumor profiling using protein biomarker panels in malignant melanoma: application of tissue microarrays and beyond.Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.Targeting MAPK pathway in melanoma therapy.Vemurafenib in melanoma.Metastatic tumor dormancy in cutaneous melanoma: does surgery induce escape?Cutaneous adverse events during vemurafenib therapy.No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model.Improving patient outcomes to targeted therapies in melanoma.What questions can a placebo answer?Drug Combinations as the New Standard for Melanoma Treatment.Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review.Anti-Cancer Drug Validation: the Contribution of Tissue Engineered Models.Epigenetically reprogramming metastatic tumor cells with an embryonic microenvironment.End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study.Dacarbazine mediate antimelanoma effects via NK cells.Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysisDelayed but Complete Response following Oral Temozolomide Treatment in Melanoma Leptomeningeal Carcinomatosis.Melanoma: the role of surgery in the era of new therapies.Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma.Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials.
P2860
Q21131978-04C06D6F-632B-472D-9466-972F11CAC63AQ24201908-FA0FDF04-BB46-4459-B1B5-A331C6EDB1DBQ24235257-1BAD5D43-DBDC-4B3D-A34D-DE9830AAE88CQ24642384-E7F9E3D4-A68A-4C77-ADEA-423F789B634DQ26751268-C6876998-F874-4CC7-821E-E8E866216059Q26853127-26CC7149-6A9B-4B8B-AA89-3B5C8FED32F7Q28241633-24D1B4E8-2445-4574-ADBC-976D79223613Q28476737-740DA309-EAEC-4149-AC65-F66F18D68DCCQ30240751-052AA265-0366-4C8F-B057-81F5CB64C6E9Q30491702-3B299A6E-B980-48F6-99C9-3096F72404FBQ30549646-5FCA75C5-FD00-4EEB-8CA1-20142745331AQ33408109-D4618823-B502-4B18-8E7D-5BBE7FFFA20FQ33408564-1C3C01DD-EE7D-431A-9525-9F1530BED1D0Q33656600-CFFDD22D-4C0D-412A-B855-0FB4EEAE4BAAQ34334499-914EC26A-EC9D-461B-B5FF-021A9742DB8EQ35026931-4F472F9F-DA78-4484-A2DB-97A48B22B713Q35584186-1FD89E2D-3743-4F88-BEEC-890AEA1AFC2FQ36916654-6220809E-1CA2-490B-BAA5-D69BB7792F0EQ37450733-09581202-3777-4FB0-BB29-2C6AD48F60BFQ38042458-40734FED-F206-40E6-839A-30ABB7FC2F52Q38050835-B4901555-027D-4B62-B6C5-2E0E23BBDE77Q38098888-4DC341CC-F4BA-4224-BC21-618C0EFA0458Q38101603-133CB101-C35E-4B40-9D40-038293CEE311Q38161337-96878AC3-9427-4E48-956B-B6780E9E0E7AQ38227760-D11969D9-8A57-4D83-A8FC-0F6A35508A2EQ38245356-1B55E599-BF0A-46DE-9BFA-B1120C48B77BQ38598702-7CEF6AB4-71F6-42F0-B0BE-06FA7585EFF2Q38823508-95EB8CFE-24B8-46E2-9A27-D12EFA3D42DDQ38836479-3E236EA1-4CE0-4650-8A77-8F99D12D9F02Q38987086-72B9F353-D74A-4234-8BFA-036AA0FBE82EQ39086783-14F063D9-D27C-4AC3-BBE0-CBC8A83DC0F1Q39148933-F2191738-EBA4-485B-B099-D6995F97A8FFQ39701144-A406588C-E058-402C-8D7D-7777B8380448Q39869759-D975F5CE-F158-47CA-8F0F-FF3F32B205E9Q40725468-EAAA1791-E57A-4702-8E55-5735CE6AE097Q41590737-D95135C9-A109-4108-B353-A50A45DD16D6Q42720641-8643210A-DBAF-4C4A-8981-CA7AB5D88F74Q42744580-089B7E46-7F6C-4AC0-A7A7-A17A7BA176CEQ43199287-7B7688D6-F894-4630-81C7-570486F99CD0Q44932310-4EEBC0EB-B564-4D83-A7EC-171DB26C99DE
P2860
Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
@ast
Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
@en
Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
@nl
type
label
Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
@ast
Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
@en
Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
@nl
prefLabel
Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
@ast
Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
@en
Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
@nl
P2093
P1476
Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
@en
P2093
Michiel Hemels
Márcio Machado
Patricia K Corey-Lisle
Philip Lui
Richard Cashin
Thomas R Einarson
P304
P356
10.1016/J.CTRV.2007.06.004
P577
2007-10-04T00:00:00Z